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Abstract
Nucleic acid-based therapeutics have the potential to provide potent and highly specific treatments
for a variety of human ailments. However, systemic delivery continues to be a significant hurdle to
success. Multifunctional nanoparticles are being investigated as systemic, nonviral delivery systems,
and here we describe the physicochemical and biological characterization of cyclodextrin-containing
polycations (CDP) and their nanoparticles formed with nucleic acids including plasmid DNA
(pDNA) and small interfering RNA (siRNA). These polycation/nucleic acid complexes can be tuned
by formulation conditions to yield particles with sizes ranging from 60–150 nm, zeta potentials from
10–30 mV, and molecular weights from ~7×107–1×109 g mol−1 as determined by light scattering
techniques. Inclusion complexes formed between adamantane (AD)-containing molecules and the
β-cyclodextrin molecules enable the modular attachment of polyethylene glycol (AD-PEG)
conjugates for steric stabilization and targeting ligands (AD-PEG-transferrin) for cell-specific
targeting. A 70-nm particle can contain ~10,000 CDP polymer chains, ~2,000 siRNA molecules,
~4,000 AD-PEG5000 molecules, and ~100 AD-PEG5000-Tf molecules; this represents a significant
payload of siRNA and a large ratio of siRNA to targeting ligand (20:1). The particles protect the
nucleic acid payload from nuclease degradation, do not aggregate at physiological salt
concentrations, and cause minimal erythrocyte aggregation and complement fixation at the
concentrations typically used for in vivo application. Uptake of the nucleic acid-containing particles
by HeLa cells is measured by flow cytometry and visualized by confocal microscopy. Competitive
uptake experiments show that the transferrin-targeted particles display enhanced affinity for the
transferrin receptor through avidity effects (multi-ligand binding). Functional efficacy of the
delivered pDNA and siRNA is demonstrated through luciferase reporter protein expression and
knockdown, respectively. The analysis of the CDP delivery vehicle provides insights that can be
applied to the design of targeted nucleic acid delivery vehicles in general.
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INTRODUCTION
Nucleic acid-based therapeutics are envisioned to play a significant role in the next generation
of treatments for a variety of diseases such as cancer. In addition to the classic gene therapy
approach of delivering DNA to replace mutated or absent genes, nucleic acid molecules can
also be used to regulate the production of disease-associated proteins at both the transcriptional
and translational levels. These nucleic acid-based drugs have received significant attention as
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promising new therapeutics, yet their application in vivo has been largely limited by the
challenge of delivery; this has been particularly true for systemic delivery.
Naked nucleic acid molecules are rapidly degraded by ubiquitous nucleases present in the
bloodstream. Double-stranded nucleic acid molecules ranging in size from small-interfering
RNAs (siRNAs) to plasmids (pDNA) have a half-life of less than one hour in serum (1–3).
Selective chemical modification of nucleic acids can increase nuclease resistance and enable
systemic delivery of naked siRNA molecules with functional efficacy in vivo (1,4). However,
even nuclease-stabilized nucleic acids must still overcome other elimination barriers such as
renal clearance that severely limit the efficacy of systemically delivered, small nucleic acid
therapeutics (5). Attachment of specific targeting ligands can induce binding to protein carriers
or uptake by the desired population of cells to be treated. Bioconjugates of the nucleic acid
therapeutics covalently attached directly to targeting ligands such as cholesterol and antibodies
have shown efficacy both in vitro and in vivo (4,6). While these methods for nuclease
stabilization and covalent attachment of targeting ligands are promising for small nucleic acid
therapeutics, the use of lipid- or polymer-based delivery vehicles is an approach for systemic
delivery that can provide functions not achievable with naked nucleic acids or their covalent
attachment to targeting moieties.
Carrier-mediated delivery has several advantages over the delivery of individual nucleic acid
molecules. Encapsulation of the payload within a lipid bilayer or through electrostatic
interactions is nonspecific, so these delivery vehicles can be used for generalized nucleic acid
delivery. The use of a carrier enables delivery of many nucleic acid molecules per uptake event
(this is especially important if the uptake involves highly specific cell-surface receptors since
they are typically low in number), and isolation from exposure to the systemic environment
can permit the use of unmodified nucleic acids (7). Modularly designed delivery vehicles can
also take advantage of covalent or non-covalent attachment of hydrophilic polymers for steric
stabilization and/or targeting ligands for cell-specific delivery, two critical features for
systemic delivery (7,8). Such modifications can affect the resulting biodistribution of delivery
vehicles through passive and/or active targeting (7–10).
Passive targeting occurs as a result of the intrinsic physicochemical properties of the delivery
vehicle. For example, the charge and size of the delivery vehicle alone can bias its
biodistribution. The charge of the delivery vehicle significantly impacts its interaction with
components of the bloodstream; highly charged particles can lead to complement activation,
while near-neutral particles exhibit reduced phagocytic uptake (11,12). Specifically, cationic
polymers such as polylysine and polyethylenimine have been shown to activate the
complement system, and increasing polycation length and surface charge density lead to higher
complement activation (11). Rapid binding of charged molecules by complement proteins or
other opsonins can lead to immune stimulation and rapid clearance of the delivery vehicles
from the bloodstream. The size of the delivery vehicle also matters for systemic delivery. Based
on measured sieving coefficients for the glomerular capillary wall, it is estimated that the
threshold for first-pass elimination by the kidneys is approximately 10 nm (diameter) (13),
placing a lower size limit on the assembled delivery vehicles. On the other end of the size
spectrum, macromolecular complexes preferentially accumulate in tumors through the
enhanced permeability and retention (EPR) effect. However, large macromolecules or delivery
vehicles exhibit limited diffusion in the extracellular space, such as the tumor interstitium, and
in the complex intracellular environment (14); in both situations, restricted movement will
severely limit efficacy by preventing uptake by a sufficient number of cells or hindering the
ability of the delivered particles to localize to intracellular compartments such as the nucleus.
Other restrictions limiting the maximum size of delivery vehicles can also be imposed by the
selectivity of receptors on certain cell types. For example, a study by Rensen et al. demonstrated
that particles larger than 70 nm in diameter were not recognized by the asialoglycoprotein
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receptor (ASGPR) (15), placing an upper size limit on the particles that can be delivered to
hepatocytes through this receptor.
Recent efforts toward targeted delivery have focused on decorating the surface of delivery
vehicles with cell surface receptor-specific targeting ligands as a means of active targeting.
Hydrophilic polymers, such as polyethylene glycol (PEG), can be attached to the surface of
the delivery vehicles to mask surface charge and prevent nonspecific interactions, helping to
prevent unwanted binding to components of the bloodstream, slow uptake by the
reticuloendothelial system (RES), and alter the cellular uptake patterns (8,16). Further addition
of entities that can interact with cell surface receptors such as the receptors’ natural ligands,
antibodies, or antibody fragments allows the delivery vehicle to target particular cell types and
undergo receptor-mediated endocytosis upon binding to the surface receptor (7,8,15).
In light of these considerations, a successful delivery vehicle must be engineered to have the
following characteristics: (i) be small enough to extravasate and exhibit adequate tissue
penetration, yet avoid rapid renal clearance; (ii) minimize nonspecific interactions and
opsonization while providing specific targeting to a given cell; and (iii) protect the nucleic acid
from degradation, but willingly release it upon arrival at the proper site. Over the past few
years, we have been developing a synthetic delivery system based on a cyclodextrin-containing
polycation (CDP) that has demonstrated some success in delivering nucleic acid payloads that
include pDNA, siRNA, and DNAzymes (7,17–20). This delivery system is the first to be de
novo designed for systemic delivery of nucleic acids and completely formulated by self-
assembly (17). Here, we describe the physicochemical and biological characterization of the
cyclodextrin-containing polycation delivery system and its formulation with nucleic acids. We
illustrate issues of importance when designing any polycation composite with nucleic acids
through the use of the CDP and point out when the conclusions are specific to this system only.
EXPERIMENTAL PROCEDURES
Formulation of nucleic acid particles
The chemical structure of the cyclodextrin-containing polycation is shown in Figure 1A. This
short, linear polycation can be synthesized with (CDP-Im) or without (CDP) the imidazole
groups on the terminal amines (17, 18). A schematic showing particle formation using CDP-
Im and nucleic acid is shown in Figure 1B; particles are formed by mixing equal volumes of
CDP-Im and nucleic acid. The ratio of positive (+) charges (2 moles of positive charge per
CDP-Im monomer; denoted β-CD) to negative (−) charges (1 mole of negative charge per
nucleotide) is defined as the formulation charge ratio (+/−). Polyethylene glycol (PEG)
molecules containing adamantane (AD) on the proximal end and either methoxy (AD-PEG)
or a targeting ligand such as transferrin (AD-PEG-Tf) on the distal end can be attached to the
surface of the particles via inclusion complex formation between adamantane and the β-CD
molecules on the polycation backbone (16, 17). The molecular weight of the PEG chain is
typically 5,000 daltons (PEG5000).
Formulation of PEGylated/targeted nucleic acid particles
Pre-complexation (self-assembly)—Before addition to the nucleic acid, the CDP or
CDP-Im was mixed with an AD-PEG conjugate at a 1:1 AD-PEG:β-CD (mol:mol) ratio in
water. Targeted particles also require the addition of ligand-modified AD-PEG-X (e.g., AD-
PEG-Tf (7,19,20)) as a percentage of the total AD-PEG in the mixture. For example, 1 mol%
AD-PEG-Tf particles contain 0.01 moles AD-PEG-Tf for every 0.99 moles AD-PEG. The
mixture of CDP (or CDP-Im), AD-PEG, and AD-PEG-Ligand in water was then added to an
equal volume of nucleic acid in water such that the ratio of positive charges from CDP or CDP-
Im to negative charges from the nucleic acid was equal to the desired charge ratio. A schematic
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of this assembly process is shown in Figure 1B. Unless specified otherwise, all PEGylated or
targeted nucleic acid particles used in this manuscript were prepared through the pre-
complexation method.
Post-complexation—Particles were initially formulated in water by mixing equal volumes
of nucleic acid and the cyclodextrin-containing polycation. After particles had formed, the AD-
PEG and AD-PEG-Tf conjugates were added directly to the formulation mixture at the desired
ratio of AD-PEG:β-CD (mol:mol). A schematic of this assembly process is shown in Figure
1B.
Electrophoretic mobility shift assay
siRNA-containing particles were formulated at different charge ratios by changing the amount
of CDP added to 1 μg of siRNA. CDP was first dissolved in 10 μL water and then added to an
equal volume of water containing 1 μg of nucleic acid. After a 30-min incubation at room
temperature, 10 μL of each formulation was run on a 1% agarose gel and visualized by ethidium
bromide staining.
Individual particle charge ratio
siRNA particles were formulated in 40 μL water at charge ratios from 5 to 30 (+/−). After
formulation, the particles were separated from the free components by addition of 400 μL PBS,
to cause particle aggregation, followed by centrifugation to pellet the aggregated particles.
Since the CDP is terminated by primary amines, quantitation of polycation content was
accomplished by measuring the amount of primary amines as follows. 400 μL of the
supernatant was removed and combined with 200 μL of 0.01% w/v 2,4,6-
trinitrobenzenesulfonic acid (Sigma). After incubating these samples for 2 h at 37°C, 200 μL
10% SDS and 100 μL of 1 N HCl were added to each sample before measuring the absorbance
at 335 nm with a spectrophotometer. The amount of CDP in each sample was determined by
comparison to a standard curve of CDP. The total positive charge present in each sample was
calculated from the mass of CDP present using the fixed charge density of 0.0014 moles “+”
per gram. This gave the number of unbound “+” charges present, so the number of bound “+”
charges in the particles could be determined by subtracting the number unbound from the total
“+” charges added during formulation. Assuming 100% incorporation of the nucleic acid into
the particles at a formulation charge ratio of 3 (+/−) (based on the electrophoretic mobility shift
assays; see Results), the ratio of CDP to nucleic acid within each particle is equal to the number
of bound “+” charges divided by the total number of “−” charges from the nucleic acid.
Serum stability
Particles were formulated in water at a charge ratio of 3 (+/−) with an siRNA concentration of
0.05 g L−1. 10 μL of 100% mouse serum (Sigma) were added to 10 μL of the particle
formulation and subsequently incubated for 4 h at 37°C and 5% CO2. 0.25 μg naked siRNA
in 5 μL water were added to 5 μL of 100% mouse serum and also incubated for 4 h at 37°C
and 5% CO2. For comparison to the t = 4 h samples, identical amounts of naked siRNA or
siRNA particles were exposed to 50% mouse serum immediately before gel loading (t = 0 h).
10 μL of each sample (containing 0.25 μg siRNA) were loaded per well of a 1% agarose gel.
Displacement of the nucleic acid from the particles was achieved by adding 1% sodium dodecyl
sulfate (SDS) to the sample immediately prior to gel loading. Gel electrophoresis was
performed by applying 100 V for 30 min, and the bands were visualized by ethidium bromide
staining.
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Dynamic light scattering (DLS)
Particle formulations were diluted to a volume of 1.4 mL, placed in a cuvette, and inserted into
a ZetaPALS (Brookhaven Instruments Corporation) instrument to measure both the size and
zeta potential. Reported effective hydrodynamic diameters represent the average values from
a total of 5–10 runs of 30 seconds each, while zeta potentials represent the average of 10 runs
each.
Transmission electron microscopy (TEM)
Particles containing CDP-Im and siRNA (0.1 g L−1) and PEGylated particles containing CDP-
Im, AD-PEG (1:1 AD-PEG:β-CD mole ratio), and siRNA (0.5 g L−1) were formulated in water
at a charge ratio of 3 (+/−). Samples were stained with 2% uranyl acetate and then examined
with an EM201C electron microscope (Philips).
Atomic force microscopy (AFM)
Particles containing CDP-Im and siRNA (0.1 g L−1) and PEGylated particles containing CDP-
Im, AD-PEG (1:1 AD-PEG:β-CD mole ratio), and siRNA (0.5 g L−1) were formulated in water
at a charge ratio of 3 (+/−). 20 μL of each formulation solution were dropped on a freshly
cleaved mica disc (Ted Pella, Inc.) and dried with pressurized air. Images were acquired with
a Digital Instruments MultiMode AFM with a Nanoscope IV controller in tapping mode at a
scan rate of 1 Hz using a BS Multi75 probe (BudgetSensors) with a resonant frequency of 75
kHz and a force constant of 3 N m−1. Height images were flattened and processed for
visualization with the derivative matrix convolution filter using WSxM scanning probe
microscopy software (Nanotec Electronica).
Isothermal titration calorimetry (ITC)
A MicroCal MCS titration calorimeter was used to investigate the thermodynamic properties
of the interaction between AD-PEG conjugates and the β-cyclodextrin molecules on the CDP-
Im backbone. CDP-Im (free or in particles) at 0.22 mM total β-CD in water was placed in the
sample cell of the instrument. The reference cell contained water alone without CDP-Im. Small
amounts of an AD-PEG stock solution at a concentration of 2.2 mM in water were titrated into
the sample cell in 25 separate 10-μL increments. Titrations were performed at 30°C. The
measured parameters were δn, the number of moles of ligand (AD-PEG) added to the sample
cell, and q, the amount of heat released or absorbed. The Simplex algorithm in the Origin data
analysis software was used to determine the following parameters: K, the equilibrium binding
constant; n, the number of available binding sites; and ΔH, the change in enthalpy. A more in
depth description of the thermodynamic analysis applied to ITC is provided by Blandamer et
al. (21).
Percentage of AD-PEG5000 bound after formulation
The small molecule, lactose (Lac), was attached to the end of AD-PEG5000 to enable
quantification using the Amplex Red Galactose Oxidase Assay Kit (Molecular Probes).
Particles were formulated in a total volume of 100 μL water by adding a 50 μL solution
containing CDP-Im and AD-PEG5000-Lac (1:1 mole ratio of AD-PEG5000-Lac: β-CD) in water
to a 50 μL solution of siRNA in water. Control formulations were created by mixing CDP-Im
and AD-PEG5000-Lac without siRNA in 100 μL water. Particles and control formulations were
filtered with Biomax (Millipore) centrifugal filtration devices with a 50 kDa MWCO to
separate free and bound components. The Amplex Red Galactose Oxidase Assay Kit
(Molecular Probes) was used to quantify the amount of AD-PEG5000-Lac in the filtrate and
retentate of all samples. Concentrations were determined by comparison to a standard curve
of AD-PEG5000-Lac. The percentage of AD-PEG5000-Lac bound to the particles was
determined by subtracting the fraction of recovered AD-PEG5000-Lac in the filtrate of the
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particle samples from the fraction of recovered AD-PEG5000-Lac in the filtrate of the control
samples.
Percentage of AD-PEG5000-Tf bound after formulation
Tf-targeted particles were formulated in a total volume of 100 μL water by adding a 50 μL
solution of CDP-Im, AD-PEG5000, and AD-PEG5000-Tf (1:1 mole ratio of AD-PEG5000-X:β-
CD where AD-PEG5000-X was composed of either 1 mol% or 5 mol% AD-PEG5000-Tf and
the remainder AD-PEG5000) in water to a 50 μL solution of siRNA in water. Control
formulations were created by mixing CDP-Im, AD-PEG5000, and AD-PEG5000-Tf without
siRNA in 100 μL water. Particles and control formulations were filtered with Nanosep
(Millipore) centrifugal filtration devices with a 300 kDa MWCO to separate free and bound
components. Total protein content in the filtrate (unbound AD-PEG5000-Tf) and retentate
(bound AD-PEG5000-Tf) was determined using the BioRad DC protein assay. The percentage
of AD-PEG5000-Tf bound to the particles was determined by subtracting the fraction of
recovered AD-PEG5000-Tf in the filtrate of the particle samples from the fraction of recovered
AD-PEG5000-Tf in the filtrate of the control samples.
Multi-angle light scattering (MALS)
Particle formulations were loaded into a 10-mL syringe connected to a syringe pump to control
the flow rate into a Dawn EOS (Wyatt Technology) multi-angle light scattering instrument.
The typical flow rate used was 1 mL min−1. Data were fit by the Astra software to the Debye
model with a detector fit degree of 2. The dn/dc value for the particles was determined to be
0.14 mL g−1, and the mass concentration used in the calculations was determined from the total
amount of CDP-Im and nucleic acid incorporated into the particles assuming an individual
particle charge ratio of 1.1 (+/−) and complete incorporation of the nucleic acid added during
formulation.
Individual particle stoichiometry
An estimate for the stoichiometry of each particle (i.e., number of CDP, nucleic acid, AD-PEG,
and AD-PEG-Tf molecules) can be calculated from the following equations.
(1)
(2)
(3)
(4)
where #NA is the number of nucleic acid molecules in the particle, #CDP is the number of
CDP monomers (β-CD) in the particle, #PEG is the number of AD-PEG molecules in the
particle, #Tf is the number of AD-PEG-Tf molecules in the particle, MWpart is the molecular
weight of an individual particle (determined by MALS), #bp is the number of base pairs per
nucleic acid molecule (e.g., 21 for siRNA), MWbp is the average molecular weight of each
nucleic acid base pair (~650 Da as an approximation), MWCDP is the molecular weight of each
CDP monomer (~1,460 Da), MWPEG is the molecular weight of each AD-PEG molecule
(~5,200 Da for AD-PEG5000), MWTf is the molecular weight of each AD-PEG-Tf molecule
(~85,000 Da for AD-PEG5000-Tf), fPEG is the fraction of the AD-PEG molecules that bind to
particles during formulation, PR is the mole ratio of AD-PEG to β-CD during formulation,
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FR is the formulation charge ratio (+/−), CR is the charge ratio (+/− = 1.1) of each individual
particle, fTf is the fraction of the AD-PEG-Tf molecules that bind to particles during
formulation, and %Tf is the mole percent AD-PEG-Tf during formulation.
Salt stability
Particle formulations were diluted to a volume of 1260 μL, placed in a cuvette, and inserted
into a ZetaPALS (Brookhaven Instruments Corporation) instrument. Kinetic studies of
aggregation were performed by recording the effective diameters at 1 minute intervals after
the addition of 1/10 volume 10X PBS to achieve a final concentration of 1X PBS,
corresponding to physiological salt concentration.
Erythrocyte aggregation
Erythrocytes were obtained from whole bovine calf blood (Rockland Immunochemicals, Inc.)
by multiple rounds of centrifugation at 700xg and 4°C for 10 min followed by removal of the
supernatant and resuspension of the pellet of erythrocytes in cold PBS (Cellgro) until the
supernatant became clear. Finally, the erythrocytes were resuspended at a concentration of 1%
(v/v). The free polycations or formulated particles were added to a 24-well plate and diluted
with PBS to a volume of 100 μL. Subsequently, 100 μL of the erythrocyte suspension were
added to each well and the plate was incubated for 1 h at 37°C. Images were taken of each well
using a CCD-IRIS/RGB (Sony) video camera attached to an Eclipse TE-300 (Nikon) inverted
microscope to visually determine the degree of aggregation.
Complement fixation
To test the complement fixation by polycations or CDP-based particles, antibody-sensitized
sheep erythrocytes were used in a CH50 assay modified from Plank et al. (11). 25 μL human
complement sera (Sigma) in gelatin veronal buffer (Sigma) were added in a 1:1.5 dilution series
across a row of wells in a 96-well plate. To this same row of wells were added 25 μL of the
desired concentration of polycation in its free form or complexed with calf thymus DNA (CT-
DNA). A different concentration of the polycations or particles was added to each row of wells.
After a 30-min incubation at 37°C, 1.25×107 antibody-sensitized sheep erythrocytes (Sigma)
were added to each well and the plate was incubated with shaking for 1 h at 37°C. Finally, the
plate was centrifuged at 2,000 RPM for 10 min, 100 μL of the supernatant from each well was
transferred to a new 96-well plate, and the absorbance at 410 nm was determined using a
SpectraMax 190 (Molecular Devices) microplate reader. This wavelength corresponds to an
absorbance peak for the hemoglobin that is released after lysis of the erythrocytes. The CH50
unit is used to define the serum dilution required to achieve 50% lysis of the antibody-sensitized
sheep erythrocytes. If the substance being tested binds complement proteins to an appreciable
degree, it will sequester these complement proteins and prevent them from binding to and
lysing the erythrocytes. As a result, a lower serum dilution (CH50) will be required to achieve
50% erythrocyte lysis under these conditions. The reported %CH50max represents the ratio of
the CH50 for the substance being tested to the CH50 determined for the complement sera alone
(CH50max).
Cellular uptake
Method 1: Flow cytometry—A FACSCalibur (BD Biosciences) flow cytometer was used
to detect the uptake of FL-siRNA (fluorescein attached to the 5’ end of the sense strand)
delivered with or without the CDP-Im delivery vehicle. HeLa cells were seeded at 2×104 cells
per well in 24-well plates 2–3 days prior to transfection and grown in medium supplemented
with 10% fetal bovine serum (FBS) and antibiotics (penicillin/streptomycin). The growth
medium was removed from each well and replaced with 200 μL Opti-MEM I (Invitrogen)
alone, 200 μL Opti-MEM I with 100 nM FL-siRNA, or 200 μL Opti-MEM I with 100 nM FL-
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siRNA formulated into CDP-Im particles at a charge ratio of 3 (+/−). After incubation for 2 h
at 37°C and 5% CO2, the transfection medium was removed and the cells were trypsinized and
resuspended in Hanks Balanced Salt Solution (HBSS) with 1% bovine serum albumin (BSA)
and 10 μg mL−1 propidium iodide to detect cell viability.
Method 2: Confocal microscopy—HeLa cells were seeded at 2×104 cells per well in a
LabTek II Chamber Slide 2 days prior to transfection and grown in medium supplemented with
10% FBS and antibiotics (penicillin/streptomycin). The growth medium was removed from
each well and replaced with 200 μL Opti-MEM I containing 100 nM FL-siRNA formulated
into CDP-Im particles at a charge ratio of 3 (+/−). After incubation for 2 h at 37°C and 5%
CO2, cells were fixed for 15 min at room temperature using 4% paraformaldehyde in PBS. F-
actin was stained with rhodamine phalloidin (Invitrogen) according to manufacturer’s
instructions. Cells were mounted with Biomeda Gel/Mount according to manufacturer’s
instructions and the coverslips were subsequently sealed using nail polish. Fluorescent images
were acquired using a Zeiss LSM 510 Meta laser scanning confocal microscope with a 40X
water-immersion objective.
Competitive uptake
Competitive uptake studies were conducted to determine the impact of free holo-transferrin
(holo-Tf) on the relative uptake of transferrin-targeted (containing 1 mol% AD-PEG5000-Tf)
or non-targeted particles. By formulating the particles with Cy3-siRNA (Cy3 attached to the
5’ end of the sense strand), a Tecan SPECTRAFluorPlus plate reader could be used to measure
the total cell-associated fluorescence after transfection. Cells were seeded at 2×104 cells per
well in 24-well plates 2–3 days prior to transfection and grown in medium supplemented with
10% FBS and antibiotics (penicillin/streptomycin). The growth medium was removed from
each well and replaced with 200 μL Opti-MEM I containing 100 nM Cy3-siRNA formulated
in particles. After incubation for 30 min at 37°C and 5% CO2, the transfection medium was
removed and the cells were lysed in 100 μL cell lysate buffer (Promega). Total fluorescence
in the 100 μL lysate per well was measured with the SPECTRAFluorPlus plate reader and the
number of siRNA molecules was estimated from a standard curve of Cy3-siRNA. Cells in two
wells that were not transfected were trypsinized and counted to provide an estimate for the
average number of cells per well.
Avidity effects
Method 1: Competitive cell-surface transferrin receptor (TfR) binding assay—
Competitive uptake experiments were performed using flow cytometry to detect the uptake of
fluorescently labeled holo-Tf. Unlabeled holo-Tf, Tf conjugates (AD-PEG5000-Tf), or Tf-
targeted siRNA particles (1 mol% AD-PEG5000-Tf) were used to compete for uptake by the
transferrin receptors on the surface of HeLa cells. Cells were seeded at 2×104 cells per well in
24-well plates 2–3 days prior to transfection and grown in medium supplemented with 10%
FBS and antibiotics (penicillin/streptomycin). The growth medium was removed from each
well and replaced with 200 μL Opti-MEM I containing 1% BSA, 20 nM AlexaFluor488-labeled
holo-Tf (AF488-Tf), and the desired unlabeled Tf competitor. After incubation for 1 h at 37°
C and 5% CO2, the transfection medium was removed and the cells were trypsinized and
resuspended in Hanks Balanced Salt Solution (HBSS) with 1% bovine serum albumin (BSA)
and 10 μg mL−1 propidium iodide to detect cell viability. To enable direct comparison of the
effects of avidity, the total amount of Tf was kept constant whether it was in its free form, as
AD-PEG5000-Tf, or as AD-PEG5000-Tf on the siRNA particles. The relative uptake under each
condition is reported as the ratio of the mean fluorescence of the wells with unlabeled
competitor to the mean fluorescence of the wells with AF488-Tf alone.
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Method 2: Live-cell binding assay—A live-cell binding assay was used to measure the
relative binding of transferrin-targeted siRNA particles. 3×105 HeLa cells were resuspended
in 100 μL PBS in individual microcentrifuge tubes and cooled on ice. To each microcentrifuge
tube were added 100 μL PBS containing PEGylated or Tf-targeted particles formulated with
Cy3-labeled siRNA such that the final Cy3-siRNA concentration was 100 nM. After incubating
for 30 minutes on ice, the microcentrifuge tubes were centrifuged for 5 minutes at 200xg to
pellet the cells. 100 μL of the supernatant from each microcentrifuge tube were added to a well
in a black 96-well plate, and the Cy3 fluorescence was measured using a Tecan Safire plate
reader. Comparison to a standard curve of Cy3-siRNA particles allowed quantification of the
amount of Cy3-siRNA in each well, and the percent bound (fraction associated with the cell
pellet) was determined by subtracting the fluorescence remaining in the supernatant from the
initial amount added.
Luciferase knockdown after siRNA transfection
Functional efficacy of pDNA and siRNA delivered by CDP-Im particles was demonstrated in
HeLa cells by co-transfecting the pGL3-CV vector (Promega) containing the firefly luciferase
gene and a non-targeting control siRNA (siCON1) synthesized by Dharmacon or a luciferase-
targeting siRNA (siLuc) synthesized by Integrated DNA Technologies. The sequence of the
siCON1 siRNA is UAGCGACUAAACACAUCAAUU (sense) and
UUGAUGUGUUUAGUCGCUAUU (antisense). The sequence of the siLuc siRNA is
GUGCCAGAGUCCUUCGAUAdTdT (sense) and UAUCGAAGGACUCUGGCACdTdT
(antisense). The Promega Luciferase Assay System was then used to quantify the relative
luciferase expression in cells that had been transfected with 1 μg pGL3-CV alone, 1 μg pGL3-
CV and 100 nM siCON1, or 1 μg pGL3-CV and 100 nM siLuc. HeLa cells were seeded at
2×104 cells per well in 24-well plates 2–3 days prior to transfection and grown in medium
supplemented with 10% FBS and antibiotics (penicillin/streptomycin). CDP-Im particles were
formulated to contain 1 μg pGL3-CV vector and 100 nM siRNA in 200 μL Opti-MEM I. The
growth medium was removed from each well and replaced with 200 μL Opti-MEM I containing
the formulated particles. After incubation for 5 h at 37°C and 5% CO2, 800 μL complete growth
medium was added to each well. 48 h later, the cells were lysed in 100 μL 1X Luciferase Cell
Culture Lysis Reagent (Promega). 10 μL of the cell lysate were added to 90 μL of the luciferase
substrate, and bioluminescence was measured using a MonoLight (Pharmingen) luminometer.
5 μL of the cell lysate were used in a BioRad DC protein assay to determine the protein
concentration in each lysate sample. Luciferase activities are reported as relative light units
per mg protein.
RESULTS AND DISCUSSION
Particle formation requires a slight excess of positive charge and protects siRNA from
degradation in serum
Results from an electrophoretic mobility shift assay (EMSA) demonstrate that siRNA particles
completely form at charge ratios (+/−) greater than ~1 to 1.5 (Figure 2A). At sufficiently high
charge ratios, the band corresponding to the free nucleic acid becomes undetectable since the
nucleic acid remains associated with the particles that have greatly reduced electrophoretic
mobility. To determine what portion of the polycations (CDP) added during formulation
actually are incorporated into the particles, the free polycations were separated from the
particles after formulation. Regardless of the formulation charge ratio up to 30 (+/−), the charge
ratio of individual particles remains ~1 (+/−) (Figure 2B). This is consistent with the results
shown in Figure 2A where charge ratios slightly greater than 1 were required to achieve
complete particle formation. A nuclease stability assay was conducted to determine if the
formation of particles could protect the nucleic acid payload from degradation by nucleases
present in serum. While naked siRNA degrades rapidly in serum, siRNA within particles is
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protected from significant degradation even after 4 hours in 50% mouse serum (Figure 3).
Additionally, the data given in Figure 3 show (i) there is essentially complete encapsulation of
the siRNA by the particles, and (ii) when the particles exposed to serum are disrupted with
SDS, the nucleic acids released are still intact siRNA duplexes.
Formulation conditions affect particle size and zeta potential
Transmission electron microscopy (TEM) and atomic force microscopy (AFM) were used to
visualize the siRNA particles formulated at a charge ratio of 3 (+/−). The images in Figure 4
demonstrate that the siRNA particles assume a roughly spherical shape, but the unPEGylated
particles display more variability in size and adopt a slightly oblong shape relative to the
PEGylated particles when they are visualized by AFM on the mica surface. While a large
fraction of the unPEGylated particles (0.1 g L−1 siRNA) have diameters that exceed 100 nm,
PEGylated particles (0.5 g L−1 siRNA) formulated with a 1:1 mole ratio of AD-PEG5000:β-
CD consistently have diameters <100 nm and are approximately 60–80 nm.
To further investigate the effects of formulation conditions, dynamic light scattering was used
to measure the effective hydrodynamic diameter and zeta potential of the particles. Consistent
with the TEM and AFM images, the results shown in Figure 5A reveal that the nucleic acid
concentration during formulation affects the size of the particles. Particles formulated with
siRNA, pDNA, and calf thymus (CT-DNA) show nearly identical trends of increased size with
higher nucleic acid concentration. However, particles that are formulated in the presence of
AD-PEG5000 (PEGylated particles formed by the pre-complexation method) do not exhibit
such a dependence on formulation conditions (Figure 5B). These properties allow the delivery
vehicles to be fine-tuned with respect to size by altering the formulation conditions accordingly
(i.e., PEGylation through the pre- or post-complexation method). The zeta potential of
unPEGylated particles ranges from 10 (particles ~60 nm in diameter) to 30 mV (particles ~150
nm in diameter), while that of PEGylated particles ranges from 10 to 20 mV for similarly sized
particles. This positive zeta potential implies that the charge ratio of the individual particles is
slightly greater than 1 (+/−). The AD-PEG5000 conjugates can be further modified to contain
targeting ligands on the distal end of the PEG chain. For example, transferrin can be conjugated
to the AD-PEG5000 molecules to yield AD-PEG5000-Tf (19). Because the transferrin protein
is negatively charged, inclusion of AD-PEG5000-Tf molecules during particle formulation
reduces the zeta potential of siRNA particles in a concentration-dependent manner (Figure 6).
Bellocq et al. reported a similar trend using particles made with pDNA (19).
AD-PEG conjugates bind to the surface of particles through inclusion complex formation
An important property of the cyclodextrin-containing polycations is their ability to form
inclusion complexes with hydrophobic molecules. This provides the opportunity for modular
attachment of different stabilizing molecules or targeting ligands through coupling to an
adamantane (AD) molecule that forms inclusion complexes with the β-cyclodextrin molecules.
Isothermal titration calorimetry was used to investigate the thermodynamics of the interaction
between AD-PEG molecules and CDP-Im either in its free form or within siRNA-containing
particles (Table 1). Figure 7 shows representative ITC data plots for binding between AD-
PEG5000 and CDP-Im formulated with siRNA at a charge ratio of 3 (+/−), CDP-Im formulated
with siRNA at a charge ratio of 10 (+/−), and CDP-Im alone. As the charge ratio increases, the
measured binding parameters approach those of free CDP-Im as expected. Given the previous
results showing the actual particle charge ratio is slightly greater than 1 (+/−), this is consistent
with the presence of excess free CDP-Im at charge ratios >1.
The value of n represents the fraction of the β-CD molecules available for inclusion complex
formation with the AD-PEG molecules. Each β-CD cup can interact with a single adamantane
molecule, as previous reports have shown a 1:1 binding stoichiometry between adamantane
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molecules and β-CD (22). While binding between individual β-cyclodextrins and AD-
PEG5000 conjugates gives the expected n value of ~1, binding between CDP-Im and AD-
PEG5000 exhibits an n value of ~0.5. When the AD-PEG5000 molecule containing a 5000-Da
PEG chain binds to a β-CD cup on the CDP-Im polymer, it likely provides steric hindrance
that impedes binding between other AD-PEG5000 molecules and nearby β-CD molecules.
Support for this hypothesis comes from the observation that the n value for binding between
CDP-Im and AD-PEG500 molecules containing short 500-Da PEG chains is 0.92 ± 0.05, likely
indicating that the shorter PEG chains do not interfere to as great an extent with the binding of
AD-PEG500 to neighboring β-CD molecules.
Another interesting pattern is observed with the ΔH values, representing the change in enthalpy
that results from binding between an AD-PEG molecule and a β-CD cup. These values are all
negative, indicating that energy is released upon binding due to the favorable interaction
between the hydrophobic adamantane and the β-CD cup. Notably, ΔH is more negative for
AD-PEG5000 binding to the siRNA particles than it is for AD-PEG5000 binding to free CDP-
Im. We hypothesize that this increased stabilization energy, in addition to the inclusion
complex formation, is a result of favorable interactions between the PEG chains themselves
when they are grouped together on the surface of an siRNA particle.
Particle molecular weight can be used to estimate individual particle stoichiometry
Determining the individual component stoichiometry of the particles provides important
insights into their functional properties. Centrifugal filtration was used to separate unbound
components from those bound to the particles. As discussed previously, it was determined that
the individual particle charge ratio (i.e., the ratio of positive charges from the CDP-Im to
negative charges from the nucleic acid) is slightly greater than 1; we used 1.1 (+/−) for the
calculations. The percent of the total AD-PEG5000 or AD-PEG5000-Tf added to the formulation
mixture that remains free was determined by quantifying the AD-PEG5000 (experiment actually
used AD-PEG5000-Lac and we assumed that the value for AD-PEG5000 would be
approximately the same) or AD-PEG5000-Tf recovered in the filtrate versus the retentate after
centrifugal filtration. The results of these measurements indicated that approximately 3% of
the total AD-PEG5000 and 10% of the total AD-PEG5000-Tf added during formulation remained
associated with the particles. The greater degree of binding measured for the AD-PEG5000-Tf
conjugates may be partly due to charge interactions between the negatively charged transferrin
proteins and the positively charged particles. The final piece of data needed to estimate the
individual particle stoichiometry is the molecular weight of the particles. This was determined
using multi-angle light scattering. The results in Figure 8 show that the molecular weight of
particles formulated with siRNA, pDNA, or calf thymus (CT-DNA) scales approximately as
r3, where r is the radius of the particle determined by DLS. This similarity between all three
types of particles is consistent with the trends observed in Figure 5, further supporting the
interesting result that formulation with a variety of nucleic acids leads to particles with similar
physical properties. An unPEGylated particle with a diameter of 70 nm is expected to have a
molecular weight around 1×108 g mol−1 from data given in Figure 8. Inserting this molecular
weight and an individual particle charge ratio of 1.1 (+/−) into Equations 1 and 2 yields 48,800
CDP monomers (or 9,750 CDP chains with a degree of polymerization of 5) and 2,110 siRNA
molecules (with 21 bp per siRNA) per particle. For the sake of calculation, we can then use
this value for #CDP to estimate the number of AD-PEG5000 and AD-PEG5000-Tf molecules
per particle using Equations 3 and 4. For example, a 70-nm siRNA particle with a molecular
weight of 1.3×108 g mol−1 (accounting for the added mass from the PEG conjugates)
formulated at a charge ratio of 3 (+/−) with 1 mol% AD-PEG5000-Tf is calculated to contain
9,750 CDP chains, 2,110 siRNA molecules, 3,950 AD-PEG5000 molecules, and 133 AD-
PEG5000-Tf molecules. The corresponding surface density for this number of AD-PEG5000
chains on a 70-nm particle is ~43 pmol cm−2 or 0.26 chains nm−2. The calculated average
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distance between PEG5000 molecules at this surface density is ~2.0 nm, while the Flory radius
is ~6 nm. Since the distance between PEG5000 molecules is much less than the Flory radius,
the PEG5000 chains are expected to interact laterally and extend out from the surface in a dense
brush layer with an estimated thickness of ~12.5 nm. Hansen et al. further examined the brush
scaling laws for polyethylene glycols and predicted that PEG5000 solutions must have monomer
volume fractions, φ, greater than 0.07–0.09 to be in the brush regime (23). This is satisfied
when the PEG5000 surface density exceeds ~26–28 pmol cm−2, again indicating that the
PEG5000 chains on the particles are in the brush regime.
PEGylation provides steric stabilization to the particles and reduces nonspecific interactions
DLS-based kinetic studies of aggregation were performed to determine whether the inclusion
of AD-PEG conjugates could help to stabilize the particles against aggregation at physiological
salt concentrations. First, the ratio of AD-PEG5000:β-CD (mol:mol) was varied from 0 to 2 to
investigate how the surface density of AD-PEG5000 affects the steric stability of siRNA
particles formulated through the post-complexation method (Figure 9A). Particles formulated
with AD-PEG5000:β-CD (mol:mol) ratios >1 do not exhibit observable aggregation after 15
minutes in 1X PBS. At ratios <1, aggregation increases as the ratio of AD-PEG5000:β-CD
(mol:mol) decreases. These results with siRNA-containing particles are consistent with those
observed by Pun et al. using particles made with pDNA (24). The length of the PEG molecule
in the AD-PEG conjugate also impacts its ability to confer steric stabilization to the particles.
As shown in Figure 9B, the stabilization effects increase with the length of the PEG chain, with
AD-PEG500 (AD-PEG500:β-CD = 1) only slightly slowing the aggregation while AD-
PEG5000 (AD-PEG5000:β-CD = 1) prevents detectable aggregation up to 15 minutes after salt
addition. If the AD-PEG500 chains, like the AD-PEG5000 chains, also achieve a surface density
of ~43 pmol cm−2 (AD-PEG500:β-CD = 1), then the average distance between PEG500 chains
remains ~2.0 nm. However, since this is not less than the Flory radius for a PEG500 molecule
(~1.5 nm), the PEG500 molecules are not expected to form the brush-like layer on the particle
surface that is needed for steric stabilization. Furthermore, modification of up to 1 mol% of
the AD-PEG5000 chains with Tf (AD-PEG5000-Tf) leads to minimal perturbations in the salt
stability of the particles. However, at 5 mol% AD-PEG5000-Tf, gradual particle aggregation
becomes apparent during the 15-minute incubation in 1X PBS.
Besides providing steric stabilization to the particles, PEGylation can help to reduce
nonspecific interactions. Specifically, experiments were performed to study the interaction
between the polycations (or particles) and erythrocytes (Figure 10). Significant erythrocyte
binding will lead to aggregation that can be observed by visual inspection using a light
microscope. While the free CDP or CDP-Im showed negligible aggregation at 0.2 g L−1, some
aggregation was observed as the concentration increased to 2 g L−1 (Figure 10A–D).
Erythrocyte aggregation was also measured after incubation with siRNA particles that were
formulated with CDP-Im and a 1:1 mole ratio of AD-PEG5000:CDP-Im (Figure 10E). The
results demonstrate that PEGylated particles do not lead to any observable aggregation at a
total CDP-Im concentration of 0.2 g L−1, corresponding to the expected concentration after
systemic delivery in vivo (7).
PEGylated particles show minimal complement fixation
Complement fixation by polyethylenimine and polylysine was compared to that of CDP or
CDP-Im. The CDP and CDP-Im molecules do not show as much complement fixation as PEI
(branched or linear) or a 36-mer of polylysine, but they do exhibit higher complement fixation
than a 5-mer of polylysine (Figure 11A). This is consistent with the notion that polycation
length and charge density can augment complement activation (11).
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Because complement fixation was observed at the physiologically relevant concentration of
0.2 g L−1, corresponding to the typical concentration of polycations in the bloodstream after
delivery of nucleic acids at a dose of 2.5 mg kg−1 (a typical dose used for in vivo siRNA delivery
(7)), experiments were performed to test particles formulated with calf thymus DNA and
stabilized by PEGylation (Figure 11B). Notably, these formulations showed minimal
complement fixation at polymer concentrations of 0.2 g L−1.
Particles achieve intracellular delivery of siRNA in vitro
The uptake of particles containing fluorescently labeled siRNA was assessed using flow
cytometry and confocal fluorescence microscopy. While naked siRNAs do not achieve
measurable levels of cellular uptake, formulation into particles with CDP-Im dramatically
increases the amount of cell-associated siRNA as measured by flow cytometry (Figure 12A).
To confirm that the siRNA was being delivered to the interior of cells, confocal fluorescence
microscopy was used to visualize cells transfected with particles containing fluorescently
labeled siRNA (Figure 12B). The internalized particles exhibited a punctate staining and were
eventually observed to accumulate in the perinuclear region.
Targeting ligands enhance cellular uptake of PEGylated particles
To verify that attachment of AD-PEG5000-Tf can lead to uptake through transferrin receptor
(TfR)-mediated endocytosis, the uptake of stabilized (PEGylated) particles was measured in
the presence or absence of free holo-Tf. While the uptake of PEGylated particles without AD-
PEG5000-Tf was not affected by the presence of free holo-Tf, the uptake of Tf-targeted particles
was reduced as a result of competition with free holo-Tf (Figure 13). Because the particles can
be internalized simultaneously by numerous mechanisms including simple pinocytosis, there
is still significant uptake even without TfR-mediated internalization under these conditions.
Targeted particles exhibit increased affinity through avidity effects
If multiple receptor/ligand interactions can occur simultaneously, then the effective affinity of
the binding interaction can be enhanced through avidity effects. Antibodies or divalent
antibody fragments are excellent examples of molecules whose binding affinities are enhanced
through avidity effects. Their divalent interactions allow single antibodies to bind two separate
receptors, leading to a stronger apparent affinity than exhibited by the monovalent antibody
fragment (25). Targeted delivery vehicles that contain multiple targeting ligands on the surface
should also display these avidity effects if multiple targeting ligands can simultaneously
interact with the receptors. A typical cancer cell may contain thousands of receptors on its
surface (26,27), and the Tf-targeted delivery vehicles can contain tens or even hundreds of Tf
ligands (depending on the percent of the AD-PEG5000 molecules with Tf molecules attached
to the distal end of the flexible PEG5000 chains) decorating each particle surface. This
arrangement should enable multiple Tf molecules to bind to TfR on the surface of the cells.
To test whether these avidity effects increase the apparent affinity of the Tf-targeted particles
for the TfR on the cell surface, a competitive uptake assay was performed using flow cytometry.
The results shown in Figure 14A demonstrate that the Tf-targeted particles possess enhanced
affinity for the TfR relative to individual AD-PEG5000-Tf molecules. Additionally, particles
without the Tf targeting ligand had a minimal impact on the uptake of the fluorescently labeled
holo-Tf. To determine how targeting ligand density affects particle binding to cell-surface TfR,
particles were incubated with HeLa cells in PBS at 4°C to measure the amount of binding in
the absence of internalization. The results shown in Figure 14B show that Tf targeting increases
the amount of cell-associated particles under these conditions, and the amount of binding
increases with the targeting ligand density.
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Particles deliver functional pDNA and siRNA to cells in vitro
In addition to achieving intracellular delivery of the nucleic acid-containing particles, the
particles need to release their nucleic acid payload intracellularly to allow it to function. Co-
delivery of a luciferase-expressing plasmid and either a control or luciferase-targeting siRNA
was used to demonstrate the ability of the particles to deliver functional pDNA and siRNA.
The luciferase activity in cell lysates was quantified using a luminometer, and relative light
units (RLU) were normalized to total cellular protein levels. As shown in Figure 15, cells that
received CDP-Im particles containing the plasmid and siRNA against luciferase (siLuc) had
luciferase activity that was ~50% lower than cells that received CDP-Im particles with either
the plasmid alone or the plasmid plus a control siRNA (siCON1).
Nanoparticles are multifunctional, integrated systems for nucleic acid delivery
The results presented here highlight the importance of creating a nanoparticle that consists of
multiple components that function together as a system, and control over size, surface
modification, payload protection, and targeting ligand to payload ratio are key parameters to
consider when designing nucleic acid delivery vehicles for in vivo systemic use. These
parameters also represent some of the major advantages of nanoparticle composites for delivery
of nucleic acids instead of using carrier-free delivery methods. Nucleic acid delivery vehicles
can help reduce renal clearance while adding features such as stabilization against nuclease
degradation, cell-specific targeting, and large payload delivery. These features make them
well-suited for the systemic delivery of nucleic acids in general, and we have shown that the
system investigated here can deliver pDNA, siRNA, and DNAzymes in vitro and in vivo (7,
17,19,20).
The capability to fine-tune the delivery vehicle’s properties combined with an understanding
of how those properties affect its function in biological systems represent two key factors
necessary for optimization of nucleic acid delivery vehicles. This study demonstrates the
importance of a rational approach in delivery vehicle design and lays a foundation for further
in vivo studies to understand the relationships between the properties of nanoparticle delivery
systems and their biological function. The approach to designing nanoparticle delivery vehicles
that is outlined here can be used for other synthetic materials and is thus not limited to the
cyclodextrin polymer-based system illustrated.
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Figure 1.
Formation of nucleic acid-containing particles using CDP-Im. (A) Schematic of the chemical
structure of CDP-Im. (B) Schematic of particle assembly.
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Figure 2.
Effect of formulation charge ratio (+/−). (A) Electrophoretic gel mobility shift assay
demonstrating the effect of formulation charge ratio on siRNA particle formation. (B)
Individual particle charge ratio as a function of formulation charge ratio.
Bartlett and Davis Page 18
Bioconjug Chem. Author manuscript; available in PMC 2008 August 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 3.
Nuclease stability of siRNA encapsulated within particles. For the t = 4 lanes, naked siRNA
or siRNA within CDP-Im particles (3 (+/−)) was incubated in 50% mouse serum for 4 h at 37°
C and 5% CO2. For the t = 0 lanes, serum was added to an equivalent amount of naked siRNA
or siRNA within CDP-Im particles immediately before loading into the gel. Addition of 1%
SDS was used to displace the siRNA from the particles to visualize the amount of intact siRNA
remaining. The first lane demonstrates that the upper bands are nonspecific bands resulting
from the interaction between SDS, serum, and the ethidium bromide stain, while the lower
bands correspond to the free siRNA.
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Figure 4.
Transmission electron microscopy (left panels) and atomic force microscopy (center and right
panels) images of (A) unPEGylated and (B) PEGylated siRNA particles formulated at a charge
ratio of 3 (+/−). Scale bar = 100 nm (left panels) and 200 nm (center and right panels).
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Figure 5.
Effect of nucleic acid concentration ([NA]) during formulation on the size of (A) unPEGylated
or (B) PEGylated particles. Particles were formulated at a charge ratio of 3 (+/−) using CDP-
Im and either siRNA, pDNA, or CT-DNA (calf thymus DNA). PEGylated particles were
formulated by adding a 1:1 mole ratio of AD-PEG5000:β-CD. Particle effective diameter was
determined using dynamic light scattering. Squares = CDP-Im/siRNA particles, circles = CDP-
Im/pDNA particles, diamonds = CDP-Im/CT-DNA particles.
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Figure 6.
Particle zeta potential as a function of AD-PEG5000-Tf ligand concentration during
formulation. Particles were formulated at a charge ratio of 3 (+/−) using CDP-Im and siRNA,
and the AD-PEG5000 or AD-PEG5000-Tf molecules were added after particle formation (post-
complexation). The total number of moles of AD-PEG5000-X (AD-PEG5000 and AD-
PEG5000-Tf) was equal to the number of moles of β-CD, and the mixture of AD-PEG5000 and
AD-PEG5000-Tf is defined by the % AD-PEG5000-Tf.
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Figure 7.
Isothermal titration calorimetry (ITC) plots characterizing the binding between AD-PEG5000
molecules and free CDP-Im or siRNA particles. (A) CDP-Im/siRNA particle (3 (+/−)) and
AD-PEG5000, (B) CDP-Im/siRNA particle (10 (+/−)) and AD-PEG5000, (C) CDP-Im and AD-
PEG5000.
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Figure 8.
Relationship between particle size and molecular weight (MW) as determined by dynamic and
multi-angle light scattering. Particles were formulated at a charge ratio of 3 (+/−) using CDP-
Im and either siRNA, pDNA, or CT-DNA. Effective diameters were measured using dynamic
light scattering, and molecular weights were determined using multi-angle light scattering.
Squares = CDP-Im/siRNA particles, circles = CDP-Im/pDNA particles, diamonds = CDP-Im/
CT-DNA particles, solid line = r3 scaling dependence of the MW of particles starting with a
MW of 7×107 g mol−1 for a 60-nm particle.
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Figure 9.
Aggregation of siRNA particles in physiological salt solutions. 140 μL of a 10X PBS solution
were added to 1260 μL of the particles in water after 5 minutes, and dynamic light scattering
was used to follow the formation of aggregates with time. (A) Effect of the ratio of AD-
PEG5000:β-CD on particle stability. CDP-Im/siRNA (3 (+/−)) particles were formulated
without AD-PEG5000 (black squares) or through the post-complexation method with an AD-
PEG5000:β-CD mole ratio of 0.25:1 (black triangles), 0.5:1 (inverted black triangles), 0.75:1
(black diamonds), 1:1 (black circles), or 2:1 (black stars). (B) Effect of PEG chain length,
adamantane conjugation, and Tf targeting ligand density on particle stability. CDP-Im/siRNA
(3 (+/−)) particles were formulated without AD-PEG5000 (black squares), with a PEG5000 (no
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adamantane):β-CD mole ratio of 1:1 (open inverted triangles), with an AD-PEG500:β-CD mole
ratio of 1:1 (black triangles), with an AD-PEG5000:β-CD mole ratio of 1:1 (black circles), or
with a 1:1 mole ratio of AD-PEG5000-X:β-CD where AD-PEG5000-X was composed of 0.1 wt
% AD-PEG5000-Tf (dark gray circles), 0.1 mol% AD-PEG5000-Tf (gray circles), 1 mol% AD-
PEG5000-Tf (light gray circles), or 5 mol% AD-PEG5000-Tf (open circles) and the remainder
AD-PEG5000.
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Figure 10.
Erythrocyte aggregation. (A) 0.2 g L−1 CDP, (B) 2 g L−1 CDP, (C) 0.2 g L−1 CDP-Im, (D) 2
g L−1 CDP-Im, (E) CDP-Im/siRNA (3 (+/−)) particles at 0.2 g L−1 CDP-Im formulated with
a 1:1 mole ratio of AD-PEG5000:β-CD, (F) PBS alone. Scale bar = 20 μm.
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Figure 11.
Complement fixation. (A) Complement fixation by free polycations. Asterisks = branched PEI,
x = linear PEI, black triangles = pentalysine, inverted black triangles = polylysine (36-mer),
black squares = CDP, black circles = CDP-Im. (B) Complement fixation by CDP/CT-DNA (3
(+/−)) particles formulated with a 1:1 mole ratio of AD-PEG5000:β-CD (black squares). The
curves for CDP (open squares), CDP-Im (open circles), and pentalysine (open triangles) are
shown again for comparison.
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Figure 12.
Uptake of CDP-Im particles containing fluorescein (FL)-labeled siRNA by HeLa cells. (A)
Histogram of cell-associated fluorescence measured by flow cytometry. The left-most peaks
correspond to the overlapping peaks for HeLa cells incubated with either Opti-MEM I alone
or 100 nM naked FL-siRNA, while the right-most peak represents the cell-associated
fluorescence after transfection with CDP-Im/FL-siRNA particles. (B) Confocal fluorescence
microscopy image of HeLa cells after transfection with CDP-Im/FL-siRNA particles (green)
and rhodamine phalloidin staining of F-actin (red). Scale bar = 50 μm.
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Figure 13.
Uptake of PEGylated and Tf-targeted particles in the presence of holo-Tf competitor. Particles
were formulated at a charge ratio of 3 (+/−) using CDP-Im and siRNA. PEGylated particles
(PEGpart) were formulated with a 1:1 mole ratio of AD-PEG5000:β-CD and Tf-targeted
particles (Tfpart) were formulated with a 1:1 mole ratio of AD-PEG5000-X:β-CD where AD-
PEG5000-X was composed of 99 mol% AD-PEG5000 and 1 mol% AD-PEG5000-Tf. Particles
containing 100 nM siRNA were added to HeLa cells in 200 μL Opti-MEM I in the absence or
presence of a 25X (moles holo-Tf: moles AD-PEG5000-Tf) excess of holo-Tf competitor.
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Figure 14.
Effect of transferrin targeting ligand density on relative binding affinity. (A) Competitive TfR
binding by free holo-Tf (circles), free AD-PEG5000-Tf (triangles), Tf-targeted CDP-Im/siRNA
(3 (+/−), 1 mol% AD-PEG5000-Tf) particles (squares), and PEGylated CDP-Im/siRNA (3 (+/
−)) particles (diamonds) in the presence of 20 nM AlexaFluor488-labeled holo-Tf. As a control,
the PEGylated particles were formulated identically to the Tf-targeted particles at each
concentration except without the addition of AD-PEG5000-Tf during formulation. (B) Live-
cell binding assay. Particles were formulated at a charge ratio of 3 (+/−) using CDP-Im and
Cy3-labeled siRNA. PEGylated particles (PEGpart) were formulated with a 1:1 mole ratio of
AD-PEG5000:β-CD and Tf-targeted particles (Tfpart) were formulated with a 1:1 mole ratio
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of AD-PEG5000-X:β-CD where AD-PEG5000-X was composed of the stated % AD-PEG5000-
Tf and the remainder AD-PEG5000. Particles containing 100 nM Cy3-siRNA were added to
HeLa cells in 200 μL PBS and incubated on ice for 30 minutes. The “percent bound” represents
the fraction of particles associated with the cell pellet after centrifugation.
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Figure 15.
Luciferase expression 48 h after co-transfection of HeLa cells with particles containing pDNA
and siRNA. Particles were formulated at a charge ratio of 3 (+/−) by combining CDP-Im with
pGL3-CV (pGL3 Alone), pGL3-CV and a control siRNA (pGL3+siCON1), or pGL3-CV and
an siRNA against luciferase (pGL3+siLuc).
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Table 1
Measured ITC parameters for the binding between AD-PEG5000 and β-CD alone, polycation alone (CDP-Im), or CDP-
Im/siRNA particles formulated at charge ratios from 3 (+/−) to 15 (+/−). For comparison, literature values are provided
for the binding between β-CD alone and adamantane carboxylate (22).
β-CD + adamantane carboxylate
n K (M−1) ΔH (cal M−1)
β-CD 1 42000 −4440
β-CD + AD-PEG5000
n K (M−1) ΔH (cal M−1)
β-CD 1.1 30600 −7358
siRNA particle + AD-PEG5000
n K (M−1) ΔH (cal M−1)
3 (+/−) 0.34 ± 0.09 5110 ± 730 −15200 ± 4090
5 (+/−) 0.38 ± 0.04 6320 ± 330 −12600 ± 570
10 (+/−) 0.48 ± 0.02 8090 ± 620 −10100 ± 520
15 (+/−) 0.49 ± 0.01 8050 ± 800 −10600 ± 450
CDP-Im 0.54 ± 0.04 8380 ± 940 −9460 ± 1490
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